CVE:LBLLattice Biologics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Lattice Biologics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add C$0.05 +0.01 (+11.11 %) (As of 06/4/2020 01:14 PM ET) Add Compare Share Today's RangeC$0.05Now: C$0.05▼C$0.0550-Day RangeC$0.05MA: C$0.09▼C$0.1352-Week RangeC$0.02Now: C$0.05▼C$0.21Volume28,400 shsAverage Volume1.96 million shsMarket CapitalizationC$4.67 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlinesSocial Media Lattice Biologics Ltd., a biotech company, develops, manufactures, and markets biologic allograft products for use in the field of cellular therapies and tissue engineering with a focus on bone, skin, and cartilage regeneration worldwide. The company offers AmnioBoost, an allograft amniotic fluid visco supplement for the treatment of joint pain associated with osteoarthritis, as well as traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix allografts. Its products are used in a range of applications, including enhancing fusion in spine surgery and breast reconstruction post mastectomy, promotion of bone regeneration in foot and ankle surgery, promotion of skull healing following neurosurgery, enhancing wound repair in burn victims, and subchondral bone defect repair in knee and other joint surgeries, as well as sports medicine indications, such as anterior cruciate ligament repair. The company is headquartered in Belgrade, Montana.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Lattice Biologics. Previous Next 2.7 Community Rank Outperform VotesLattice Biologics has received 67 “outperform” votes. (Add your “outperform” vote.)Underperform VotesLattice Biologics has received 59 “underperform” votes. (Add your “underperform” vote.)Community SentimentLattice Biologics has received 53.17% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Lattice Biologics and other stocks. Vote “Outperform” if you believe LBL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LBL will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldLattice Biologics does not currently pay a dividend.Dividend GrowthLattice Biologics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lattice Biologics insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Lattice Biologics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lattice Biologics is -5.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.54 out of 5 stars Industry, Sector and Symbol Stock Exchange CVE Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolCVE:LBL Previous Symbol CUSIPN/A CIKN/A Webwww.latticebiologics.com Phone+1-604-2356701Debt Debt-to-Equity RatioN/A Current Ratio0.13 Quick Ratio0.06Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesC$2.42 million Price / Sales1.93 Cash FlowN/A Price / Cash FlowN/A Book ValueC($0.07) per share Price / Book-0.74Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares93,458,000Market CapC$4.67 million Next Earnings Date9/3/2020 (Estimated) OptionableNot Optionable TSXV:LBL Rates by TradingView Receive LBL News and Ratings via Email Sign-up to receive the latest news and ratings for LBL and its competitors with MarketBeat's FREE daily newsletter. Lattice Biologics (CVE:LBL) Frequently Asked Questions How has Lattice Biologics' stock been impacted by COVID-19 (Coronavirus)? Lattice Biologics' stock was trading at C$0.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, LBL stock has increased by 66.7% and is now trading at C$0.05. View which stocks have been most impacted by Coronavirus. When is Lattice Biologics' next earnings date? Lattice Biologics is scheduled to release its next quarterly earnings announcement on Thursday, September 3rd 2020. View our earnings forecast for Lattice Biologics. Has Lattice Biologics been receiving favorable news coverage? Press coverage about LBL stock has been trending somewhat positive recently, InfoTrie reports. The research group rates the sentiment of media coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Lattice Biologics earned a media sentiment score of 1.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutLattice Biologics. Who are some of Lattice Biologics' key competitors? Some companies that are related to Lattice Biologics include cbdMD (YCBD), Invion (IVX), Pediapharm (MDP), Diurnal Group (DNL), Viridium Pacific Group (VIR), Zomedica Pharmaceuticals (ZOM), Cipher Pharmaceuticals (CPH), Indiva (NDVA), Harvest One Cannabis (HVT), MGC Pharmaceuticals (MXC), Eve & Co Inc (EVE), SugarBud Craft Growers (SUGR), Evgen Pharma (EVG), NeutriSci International (NU) and Cannpal Animal Therapeutics (CP1). View all competitors. What other stocks do shareholders of Lattice Biologics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lattice Biologics investors own include Cross Timbers Royalty Trust (CRT), Grenville Strategic Royalty (GRC), InfraCap MLP ETF (AMZA), Alliance Resource Partners (ARLP), ARBOR RLTY TR I/SH (ABR), Advanced Emissions Solutions (ADES), Archer Daniels Midland (ADM), AGNC Investment (AGNC), Aphria (APHA) and Apple Hospitality REIT (APLE). Who are Lattice Biologics' key executives? Lattice Biologics' management team includes the following people: Mr. Guy S. Cook, CEO, Pres & Director (Age 54) What is Lattice Biologics' stock symbol? Lattice Biologics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "LBL." How do I buy shares of Lattice Biologics? Shares of LBL and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab. What is Lattice Biologics' stock price today? One share of LBL stock can currently be purchased for approximately C$0.05. How big of a company is Lattice Biologics? Lattice Biologics has a market capitalization of C$4.67 million and generates C$2.42 million in revenue each year. What is Lattice Biologics' official website? The official website for Lattice Biologics is www.latticebiologics.com. How can I contact Lattice Biologics? Lattice Biologics' mailing address is 16701 N 90th St Ste 101, SCOTTSDALE, AZ 85260-1012, United States. The company can be reached via phone at +1-604-2356701. This page was last updated on 6/4/2020 by MarketBeat.com Staff
